
On Monday, Bavarian Nordic announced that a license and supply agreement has been completed with Shanghai-based biotech company Nuance Pharma, regarding the rights for the Danish company’s RSV vaccine candidate, a stock notification reports.
Bavarian is set to receive an upfront payment of USD 12.5m, and the deal also entails potential milestone payments of up to USD 212.5m.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app